Literature DB >> 31828683

Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.

Hamed Ebrahimzadeh Leylabadlo1,2,3, Reza Ghotaslou4,5, Hossein Samadi Kafil1,6, Mohammad Mehdi Feizabadi7, Seyed Yaghoub Moaddab1, Safar Farajnia8, Elham Sheykhsaran9, Sarvin Sanaie2,3, Dariush Shanehbandi10, Hossein Bannazadeh Baghi6,10.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the well-known disease of the liver in adults and children throughout the world. The main manifestations related to NAFLD are an unusual storage of lipid in hepatocytes (hepatic steatosis) and progression of inflammation for non-alcoholic steatohepatitis (NASH). NAFLD is described as a multifactorial complication due to the genetic predisposition, metabolic functions, inflammatory, gut microbiota (GM), and environmental factors. The GM dysregulation among these factors is correlated to NAFLD development. In recent decades, advanced microbial profiling methods are continuing to shed light on the nature of the changes in the GM caused by NASH and NAFLD. In the current review, we aim to perform a literature review in different library databases and electronic searches (Science Direct, PubMed, and Google Scholar) which were randomly obtained. This will be done in order to provide an overview of the relation between GM and NAFLD, and the role of prebiotics, probiotics, and fecal microbiota transplantation (FMT), as potential therapeutic challenges for NAFLD.

Entities:  

Keywords:  Microbiome; Microbiota; Non-alcoholic fatty liver disease; Prebiotics; Probiotics

Year:  2019        PMID: 31828683     DOI: 10.1007/s10096-019-03746-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  125 in total

Review 1.  The role of short-chain fatty acids in health and disease.

Authors:  Jian Tan; Craig McKenzie; Maria Potamitis; Alison N Thorburn; Charles R Mackay; Laurence Macia
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 2.  Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.

Authors:  Karen D Corbin; Steven H Zeisel
Journal:  Curr Opin Gastroenterol       Date:  2012-03       Impact factor: 3.287

3.  Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation.

Authors:  Da Zhou; Qin Pan; Xiao-Lin Liu; Rui-Xu Yang; Yuan-Wen Chen; Chang Liu; Jian-Gao Fan
Journal:  J Gastroenterol Hepatol       Date:  2017-09       Impact factor: 4.029

4.  Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.

Authors:  Brian C Ferslew; Guoxiang Xie; Curtis K Johnston; Mingming Su; Paul W Stewart; Wei Jia; Kim L R Brouwer; A Sidney Barritt
Journal:  Dig Dis Sci       Date:  2015-07-03       Impact factor: 3.199

5.  Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function.

Authors:  Caleb J Kelly; Leon Zheng; Eric L Campbell; Bejan Saeedi; Carsten C Scholz; Amanda J Bayless; Kelly E Wilson; Louise E Glover; Douglas J Kominsky; Aaron Magnuson; Tiffany L Weir; Stefan F Ehrentraut; Christina Pickel; Kristine A Kuhn; Jordi M Lanis; Vu Nguyen; Cormac T Taylor; Sean P Colgan
Journal:  Cell Host Microbe       Date:  2015-04-09       Impact factor: 21.023

6.  Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

Authors:  Shani Ben-Shlomo; Isabel Zvibel; Mati Shnell; Amir Shlomai; Elena Chepurko; Zamir Halpern; Nir Barzilai; Ran Oren; Sigal Fishman
Journal:  J Hepatol       Date:  2010-10-26       Impact factor: 25.083

7.  [Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease].

Authors:  W Wang; L P Shi; L Shi; L Xu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2018-02-01

8.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

9.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

10.  High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects.

Authors:  Greta Jakobsdottir; Jie Xu; Göran Molin; Siv Ahrné; Margareta Nyman
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more
  6 in total

1.  A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo.

Authors:  Iris Pinheiro; Aurora Barberá; Imma Raurell; Federico Estrella; Marcel de Leeuw; Selin Bolca; Davide Gottardi; Nigel Horscroft; Sam Possemiers; María Teresa Salcedo; Joan Genescà; María Martell; Salvador Augustin
Journal:  Biomedicines       Date:  2022-05-20

Review 2.  Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.

Authors:  Yi-Hsun Chen; Wei-Kai Wu; Ming-Shiang Wu
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

Review 3.  Role of ALDH2 in Hepatic Disorders: Gene Polymorphism and Disease Pathogenesis.

Authors:  Qiaoling Wang; Binxia Chang; Xiaoyan Li; Zhengsheng Zou
Journal:  J Clin Transl Hepatol       Date:  2021-01-04

Review 4.  The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis.

Authors:  Hui Xiang; Dating Sun; Xin Liu; Zhi-Gang She; Yonghong Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-08       Impact factor: 5.555

5.  Oral administration of branched-chain amino acids ameliorates high-fat diet-induced metabolic-associated fatty liver disease via gut microbiota-associated mechanisms.

Authors:  Ranran Zhang; Hongna Mu; Ziyun Li; Jie Zeng; Qi Zhou; Hongxia Li; Siming Wang; Xianghui Li; Xianghui Zhao; Liang Sun; Wenxiang Chen; Jun Dong; Ruiyue Yang
Journal:  Front Microbiol       Date:  2022-07-22       Impact factor: 6.064

Review 6.  Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation.

Authors:  Sergii Tkach; Andrii Dorofeyev; Iurii Kuzenko; Nadiya Boyko; Tetyana Falalyeyeva; Luigi Boccuto; Emidio Scarpellini; Nazarii Kobyliak; Ludovico Abenavoli
Journal:  Medicina (Kaunas)       Date:  2022-01-06       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.